Eplerenone in hypertension

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2573-2581

  Burgess, Ellen ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

Aldosterone; Eplerenone; Hypertension

Indexed keywords

AMLODIPINE; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LOSARTAN; PROGESTERONE RECEPTOR; SPIRONOLACTONE;

AFRICAN AMERICAN; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; KIDNEY DISEASE; LIBIDO DISORDER; MASTALGIA; MENSTRUATION DISORDER; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PROTEIN FUNCTION; PUBLISHING; RESPIRATORY TRACT DISEASE; REVIEW; SEXUAL DYSFUNCTION; TREATMENT FAILURE;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; ENALAPRIL; EXPERT TESTIMONY; HUMANS; HYPERTENSION; SPIRONOLACTONE;

EID: 10644243629     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2573     Document Type: Review

References (14)

1. WILLIAMS JS, WILLIAMS GH: 50th anniversary of aldosterone. J. Clin. Endocrinol. Metab. (2003) 88:2364-2372.
2. HOLLENBERG NK: Aldosterone in the development and progression of renal injury. Kidney Int. (2004) 66:1-9.
3. PITT B, ZANNAD F, REMME W: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. (1999) 341:709-717.
4. PITT B, REMME W, ZANNAD F et al., for the EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
5. WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15:709-716.
6. WHITE WB, CARR AA, KRAUSE S, JORDAN R, RONIKER B, OIGMAN W: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. (2003) 92:38-42.
7. WILLIAMS GH, BURGESS E, KOLLOCH RE et al.: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. (2004) 93:990-996.
8. KRUM H, NOLLY H, WORKMAN D et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2003) 40:117-123.
9. FLACK JM, OPARIL S, PRATT JH et al.: Efficacy and tolerability of eplerenone and losartan in black and white patients. J. Am. Coll. Cardiol. (2003) 41:1148-1155.
10. WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41:1021-1026.
11. HOLLENBERG NK, WILLIAMS GH, ANDERSON R, AHKRAS KS, BITTMAN RM: Symptoms and the distress they cause. Comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch. Intern. Med. (2003) 163:1543-1548.
12. PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-Left Ventricular Hypertrophy Study. Circulation (2003) 108 1831-1838.
13. BURGESS E, LACOURCIERE Y, RUILOPE LM et al.: Assessment of the long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension: Clin. Ther. (2003) 25:2388-2404.
14. SICA DA: Eplerenone: a new aldosterone receptor antagonist - are the FDA's restrictions appropriate? J. Clin. Hypertens. (2002) 4:441-445.